Sanofi was criticized by a U.K. trade group, which accused it of making misleading claims about its RSV vaccine and ...

Feb 2 (Reuters) - Sanofi has breached the UK pharma code of practice with unsubstantiated claims that its Beyfortus was more ...

Pfizer (NYSE:PFE) agreed to acquire weight loss drug developer Metsera for US$10b, entering the obesity and GLP-1 market. The ...

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Pfizer (NYSE:PFE) has entered a non exclusive licensing agreement with Novavax for access to its Matrix-M adjuvant technology. The company is also participating in the White House TrumpRx initiative, ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

The 2025-26 Pfizer COVID-19 vaccine is about 57% effective against emergency department/urgent care (ED/UC) visits and 54% ...

The pharma company had to scale vaccine production from 200 million annually to 3 billion at the pandemic's peak.

Albert Bourla admitted to going to extreme lengths to “save the world” and get the vaccines out faster during the COVID-19 ...

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.